HPV Vaccination Delivers Better ROI Earlier Than Later
The journal PLOS published a cost-effectiveness analysis on March 11, 2021, using models that are part of the Cancer Intervention and Surveillance Modeling Network (CISNET) to evaluate the cost-effectiveness of extending HPV vaccination in females and males up to ages 30, 35, 40, or 45 years.
This study found HPV vaccination of women and men aged 30 to 45 years provides limited health benefits at the population level, at a substantial cost (HPV vaccine prices).
This sensitivity analysis revealed that assumptions about cervical screening compliance, vaccine costs, and the natural history of noncervical HPV-related cancers could have major impacts on the vaccination strategies' estimated cost-effectiveness.
However, even with the most extreme assumptions, both models almost universally found that the cost-effectiveness of HPV vaccination for adults aged 30 to 45 years was greater than $200,000 per QALY.
'Where possible, we erred in the direction of making assumptions that were favorable to increasing the age of vaccination, including assuming no delay between the reduction in HPV infections from vaccination and the reduction in genital warts,' concluded these researchers.
A nonavalent human papillomavirus vaccine (Gardasil 9) has been licensed for women and men up to age 45 years in the USA.